NodThera Inc. Changes Name to Rezera Inc. and Announces Ruvonoflast Phase 3 Development Program
September 9, 2026
Rezera plans to advance ruvonoflast into a Phase 3 clinical trial in peripheral artery disease (PAD) in H1 of 2027 Boston, MA, September 9, 2026